All In Biotech

NDA 214846 · Sumitomo Pharma Am

Myfembree

Estradiol, Norethindrone Acetate, Relugolix · Oral · Gonadotropin Releasing Hormone Receptor Antagonist

Last checked: Nov 19, 2026Latest source record: Aug 27, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2021

May 26, 2021

Approved uses

4

Original approval plus efficacy supplements

Registered trials

1,701

351 Phase 3, 176 recruiting

FAERS reports

1,516

162 serious, 1 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

Boxed warning

WARNING: THROMBOEMBOLIC DISORDERS AND VASCULAR Events Estrogen and progestin combinations, including MYFEMBREE, increase the risk of thrombotic or thromboembolic disorders, including pulmonary embolism (PE), deep vein thrombosis (DVT), stroke and myocardial infarction (MI), especially in women at increased risk for these events [see Warnings and Precautions ( 5.1 )] MYFEMBREE is contraindicated in women with current or a history of thrombotic or thromboembolic disorders and in women at increased risk for these events, including women over 35 years of age who smoke or women with uncontrolled hypertension [see Contraindications ( 4 )]. WARNING: THROMBOEMBOLIC DISORDERS AND VASCULAR EVENTS See full prescribing information for complete boxed warning Estrogen and progestin combinations, including MYFEMBREE, increase the risk of thrombotic or thromboembolic disorders, especially in women at...

What it is approved for

From the label in effect Oct 27, 2026.

MYFEMBREE is a combination of relugolix, a gonadotropin-releasing hormone (GnRH) receptor antagonist, estradiol, an estrogen, and norethindrone acetate, a progestin, indicated in premenopausal women for the: management of heavy menstrual bleeding associated with uterine leiomyomas (fibroids). ( 1.1 , 14.1 ) management of moderate to severe pain associated with endometriosis. ( 1.2 , 14.2 ) Limitations of Use Use of MYFEMBREE should be limited to 24 months due to the risk of continued bone loss which may not be reversible. ( 1.3 , 5.2 , 6 ) 1.1 Heavy Menstrual Bleeding Associated with Uterine Leiomyomas MYFEMBREE is indicated for the management of heavy menstrual bleeding associated with uterine leiomyomas (fibroids) in premenopausal women [see Clinical Studies ( 14 )] . 1.2 Moderate to Severe Pain Associated with Endometriosis MYFEMBREE is indicated for the management of moderate to severe pain associated with endometriosis in premenopausal women [see Clinical Studies ( 14 )] . 1.3 Limitations of Use Use of MYFEMBREE should be limited to 24 months due to the risk of continued bone loss that may not be reversible [see Warnings and Precautions ( 5.2 ) and Adverse Reactions ( 6 )] .

Mechanism: MYFEMBREE is a combination of relugolix, estradiol (E2), and norethindrone acetate (NETA). Relugolix is a non-peptide GnRH receptor antagonist that competitively binds to pituitary GnRH receptors, thereby reducing the release of luteinizing hormone (LH) and follicle-stimulating hormone (FSH), leading to decreased serum concentrations of the ovarian sex hormones estradiol and progesterone and reduced bleeding associated with uterine fibroids and pain associated with endometriosis. Estradiol acts by binding to nuclear receptors that are expressed in estrogen-responsive tissues. As a component...

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

1 products under this application
  • MYFEMBREE · ESTRADIOL 1MG; NORETHINDRONE ACETATE 0.5MG; RELUGOLIX 40MG · TABLET, ORAL · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Estradiol" as an intervention, any sponsor and status, largest first.

All 1,701 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • therapy interrupted472
  • heavy menstrual bleeding233
  • intermenstrual bleeding118
  • headache74
  • off label use72
  • hot flush70
  • alopecia68
  • menstruation irregular62
  • dysmenorrhoea60
  • nausea51
  • pain45
  • drug ineffective40

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
202166
2022241
2023542
2024481
2025108
202678

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Myfembree (Relugolix/Estradiol/Norethindr)

2024 spending

$2.1M

Beneficiaries

391

1,412 claims

Per beneficiary

$5,448

$41.52 per unit

View as table
YearSpending
2020$0
2021$57,958
2022$616,182
2023$1,714,893
2024$2,130,181

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 6,473 on PubMed

Sponsor: Sumitomo Pharma Am

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.